Virtual | Virtual

Event Title

Decentralized Clinical Trials (DCT) Draft Guidance

June 20, 2023

Date:: June 20, 2023
Time:: 3:00 PM - 4:00 PM ET

Topic & Presentations	Speakers
Decentralized Clinical Trials (DCT) Draft Guidance
Intro - Decentralized Clinical Trials for Drugs, Biological Products, and Devices	Leonard Sacks, MBBCh Associate Director Clinical Methodologies Office of Medical Policy (OMP) \| CDER \| FDA
Overview of the DCT Draft Guidance	Ryan Robinson, MD Medical Officer Clinical Methodologies OMP \| CDER \| FDA
Q&A Discussion Panel	Same as above

Visit CDER Small Business and Industry Assistance Page

ABOUT THIS WEBINAR

The FDA sees important potential benefits and value in DCTs. Advances in clinical care using electronic communications and information technology to interact with trial participants in different locations (i.e., telehealth) allow for fewer in-person visits to clinical trial sites and facilitate decentralization. In addition, digital health technologies have expanded the types of trial-related data that can be obtained remotely from trial participants. By enabling remote participation, DCTs may enhance convenience for trial participants, reduce the burden on caregivers, expand access to more diverse patient populations, improve trial efficiencies, and facilitate research on rare diseases and diseases affecting populations with limited mobility. As part of the FDA’s efforts to be responsive to the rapidly evolving clinical trial landscape and clarify the Agency’s recommendations on the conduct of DCTs, the FDA will provide an overview of the draft guidance titled Decentralized Clinical Trials for Drugs, Biological Products, and Devices.

TOPICS COVERED

Design of a DCT
Conduct of remote clinical trial visits and clinical trial-related activities in a DCT
Use of digital health technologies to remotely acquire data in a DCT
Roles and responsibilities of the sponsor and investigators in a DCT
Obtaining informed consent and institutional review board oversight of the informed consent process in a DCT
Determination of the appropriateness of investigational products for use in a DCT
Packaging and shipping of investigational products in a DCT
Safety monitoring of trial participants in a DCT
Software used to support the conduct of a DCT

INTENDED AUDIENCE

Entities (e.g. sponsors, contract research organizations) designing clinical investigations which incorporate decentralized elements or who submit INDs/IDEs
Developers of DCT software or digital health technologies
Clinical trial personnel or other healthcare professionals involved in clinical investigations using decentralized elements
Patients (or caregivers of patients) participating in DCTs
Regulators involved in the use of DCT data to support marketing applications

FDA RESOURCES

Event Materials

Title	File Type/Size
Decentralized Clinical Trials (DCT) Draft Guidance_June_30_2023.pdf	pdf (318.37 KB)